Considering that arthritis and arthralgia are based on a complex inflammatory process, CDK4/6 inhibitors may attenuate E2F2 activity in synovium and cartilage and reverse, at least in part, the inflammation caused by aromatase inhibitors. The gene discussed is CYP19A1; the disease is Arthritis.